Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Patients typically experience decreased hunger, faster satiety, reduced cravings, and increased energy, alongside improved cardiovascular and metabolic health markers
This is the first therapeutic dose where most people begin noticing appetite suppression
Shh-FOXA2 signaling is the second major signaling event involved in midbrain formation
Pregnant or breastfeeding women should consult a healthcare provider before use
Beyond these primary endpoints, TRIUMPH-1 includes a range of secondary and exploratory endpoints that paint a fuller picture of retatrutide's clinical impact: Proportion of participants achieving 10%, 15%, and 20% or greater weight loss Changes in waist circumference Changes in cardiometabolic risk factors, including blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, and fasting glucose Changes in HbA1c (a measure of average blood sugar over the preceding two to three months) Changes in liver enzymes and markers of hepatic health Patient-reported outcomes related to quality of life and physical function Safety and tolerability, including the incidence and severity of adverse events The secondary endpoints are particularly important for retatrutide because the Phase 2 data showed striking improvements across metabolic markers
US$ 22.12
US$ 28.28
US$ 27.56
US$ 26.70
US$ 25.15
US$ 25.51
